Brief: Karolinska Development's Portfolio Co Secures Funding For Development Of Golexanolone

Kdventures AB

28/03/2023 08:00

March 28 (Reuters) - Karolinska Development AB
 KDEV.ST :
    * KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY UMECRINE
COGNITION
SECURES ADDITIONAL FUNDING FOR FURTHER DEVELOPMENT OF
GOLEXANOLONE
    * PARTICIPATES IN FINANCING ROUND AS PART OF AN INVESTOR
CONSORTIUM THAT BRINGS UMECRINE COGNITION A TOTAL OF SEK 31.6
MILLION
    * DILUTIVE EFFECT OF TRANSACTION WILL RESULT IN A NEGATIVE
EARNINGS EFFECT OF SEK 19.7 MILLION FOR KAROLINSKA DEVELOPMENT
IN Q1 OF 2023
    * FUNDING WILL BE USED TO FINANCE CLINICAL PHASE 2 TRIAL OF
GOLEXANOLONE IN PRIMARY BILIARY CHOLANGITIS AMD PRECLINICAL
STUDIES WITHIN PARKINSON'S DISEASE

Source text for Eikon:  ID:nGNEWp9jG 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))